The company has developed a multiplex panel for bacterial and yeasts infections that it plans to submit for FDA clearance in 2027.
A new tool greatly improves scientists' ability to identify and study proteins that regulate gene activity in cells, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback